Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Cancer Vaccines01:30

Cancer Vaccines

237
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
237
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.4K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the Sodium Content: A Case Series of Benign and Malignant Renal Tumours Using <sup>23</sup>Na-MRI at 3 T.

NMR in biomedicine·2026
Same author

Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline.

JCO oncology practice·2026
Same author

Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial.

Nature communications·2026
Same author

Coupling dead cell recognition to Fcγ receptors augments anticancer immunity.

Nature cancer·2026
Same author

Exploratory analysis of PTEN deficiency by immunohistochemistry from the Phase III CAPItello-291 trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Oral Regimens for AML Make Strides.

Cancer discovery·2026
Same journal

Tumor microbial burden drives immune responses through regulation of Interferon signaling.

Cancer discovery·2026
Same journal

Spatial multi-omics implicate the interaction between Tpex and B cells in tertiary lymphoid structures after neoadjuvant therapy.

Cancer discovery·2026
Same journal

RNA-Triggered Chromatin Shredding Hits Cancer's Hardest Targets.

Cancer discovery·2026
Same journal

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.

Cancer discovery·2026
Same journal

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
See all related articles

Related Experiment Video

Updated: May 9, 2025

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.5K

MANIFEST: Multiomic Platform for Cancer Immunotherapy.

Kok Haw Jonathan Lim1,2, Zayd Tippu3,4, Pippa G Corrie5

  • 1Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.

Cancer Discovery
|May 2, 2025
PubMed
Summary
This summary is machine-generated.

Immunotherapy shows promise for cancer patients, but reliable biomarkers are needed. This study introduces a multi-omics platform to identify biomarkers for predicting treatment response and toxicity using AI.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Related Experiment Videos

Last Updated: May 9, 2025

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.8K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.3K

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Cancer immunotherapy has improved patient survival rates.
  • Current limitations include a lack of reliable biomarkers for predicting treatment response and toxicity.
  • There is a critical need for tools to personalize immunotherapy decisions.

Purpose of the Study:

  • To introduce a novel, tumor type-agnostic platform for deep patient profiling in immunotherapy.
  • To enable the integrative identification of biomarkers for immunotherapy response and toxicity.
  • To discover novel therapeutic targets using advanced computational methods.

Main Methods:

  • Development of the Multiomic ANalysis of Immunotherapy Features Evidencing Success and Toxicity (MANIFEST) platform.
  • Application of artificial intelligence and machine learning for data analysis.
  • Deep profiling of patients undergoing immunotherapy.

Main Results:

  • The MANIFEST platform facilitates comprehensive analysis of multi-omic data.
  • The platform enables the identification of potential biomarkers for immunotherapy outcomes.
  • Initial findings suggest the potential for discovering new therapeutic targets.

Conclusions:

  • The MANIFEST platform addresses the unmet need for immunotherapy biomarkers.
  • This approach holds promise for personalizing cancer treatment and improving patient outcomes.
  • Further validation and application of the platform are warranted.